The Motley Fool

Pam Narang

Smith & Nephew: are shares in this FTSE 100 company a buy?

Smith+Nephew is a FTSE 100 company that has been rocked by the pandemic, but early signs point to recovery. Is it a good investment... More »

AstraZeneca stock: time to sell?

Looking beyond the company’s vaccine woes, is now the time to make the most of the uptick in AstraZeneca stock and sell out? More »

1 mining stock to watch

The price of mining stock, and particularly gold, has fluctuated in response to the global pandemic, offering potential short-term buy opportunities. More »

3 pharma stocks to watch in April

Pharma stocks are rarely a bad bet in the long term, but risk can vary widely and should be weighed judiciously on a case-by-case... More »

Are GlaxoSmithKline shares under-valued?

GlaxoSmithKline shares are likely under-priced given the company’s current market position, near-term strategy and future pipeline prospects. More »